Principal Investigator
Gerald Soff
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20260095
Clinical Trial Summary
A Phase 2 open label study to evaluate the tolerability of ianalumab (VAY736) with investigators choice thrombopoietin receptor agonist (IC TPO-RA) in patients with primary immune thrombocytopenia (ITP) previously treated with at least one treatment (VAY2EXPLORE)
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Classical Hematology
Contact Information
Phone Number
305-243-2647